Oberweis Asset Management Inc Argenx Se Transaction History

Oberweis Asset Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$106.59 - $164.21 $16.2 Million - $24.9 Million	-151,908 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$113.31 - $150.51 $19.3 Million - $25.6 Million	-170,092 Reduced 52.82%	151,908 $17.3 Million
Q2 2019 Aug 14, 2019	BUY	$115.0 - $141.58 $1.73 Million - $2.12 Million	15,000 Added 4.89%	322,000 $45.6 Million
Q1 2019 May 15, 2019	BUY	$98.85 - $134.59 $1.89 Million - $2.57 Million	19,100 Added 6.63%	307,000 $38.3 Million
Q4 2018 Feb 14, 2019	BUY	$63.81 - $109.82 $18.4 Million - $31.6 Million	287,900 New	287,900 $27.7 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.3B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Oberweis Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Oberweis Asset Management Inc with notifications on news.